Analysts Offer Predictions for TG Therapeutics Q3 Earnings

Key Points

• Analysts predict TG Therapeutics will report Q3 2025 earnings of $0.20 per share, with a price target of $60.00 from HC Wainwright.
• The company reported a 92.1% year-over-year revenue increase in its last quarterly results, generating $141.15 million.
• Currently, TG Therapeutics holds a consensus rating of "Moderate Buy", with an average target price of $49.00 across six analysts.

TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) - Stock analysts at HC Wainwright issued their Q3 2025 EPS estimates for shares of TG Therapeutics in a note issued to investors on Monday, October 6th. HC Wainwright analyst E. Bodnar expects that the biopharmaceutical company will post earnings of $0.20 per share for the quarter. HC Wainwright currently has a "Buy" rating and a $60.00 price target on the stock. The consensus estimate for TG Therapeutics' current full-year earnings is $0.08 per share. HC Wainwright also issued estimates for TG Therapeutics' Q4 2025 earnings at $0.23 EPS, FY2025 earnings at $0.63 EPS, FY2026 earnings at $1.60 EPS, FY2027 earnings at $1.93 EPS and FY2028 earnings at $2.45 EPS.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.32 by ($0.15). TG Therapeutics had a return on equity of 26.05% and a net margin of 13.31%.The firm had revenue of $141.15 million for the quarter, compared to analysts' expectations of $147.76 million. During the same period last year, the firm earned $0.04 EPS. The business's quarterly revenue was up 92.1% on a year-over-year basis. TG Therapeutics has set its FY 2025 guidance at EPS.

A number of other brokerages have also issued reports on TGTX. The Goldman Sachs Group raised TG Therapeutics to a "hold" rating and set a $37.00 price objective for the company in a report on Thursday, July 10th. B. Riley increased their price target on TG Therapeutics from $53.00 to $55.00 and gave the stock a "buy" rating in a research note on Wednesday, September 17th. Finally, Weiss Ratings reissued a "hold (c-)" rating on shares of TG Therapeutics in a research note on Saturday, September 27th. Four research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $49.00.

TG Therapeutics Price Performance

Shares of TGTX stock opened at $36.50 on Wednesday. The firm has a fifty day moving average of $31.56 and a two-hundred day moving average of $35.36. TG Therapeutics has a 1-year low of $21.18 and a 1-year high of $46.48. The firm has a market cap of $5.79 billion, a P/E ratio of 98.65 and a beta of 1.97. The company has a debt-to-equity ratio of 0.89, a current ratio of 3.86 and a quick ratio of 2.96.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Johnson Financial Group Inc. purchased a new position in TG Therapeutics during the 2nd quarter valued at about $25,000. Ameritas Advisory Services LLC purchased a new position in TG Therapeutics during the second quarter valued at approximately $25,000. NBC Securities Inc. grew its holdings in shares of TG Therapeutics by 82,300.0% during the 1st quarter. NBC Securities Inc. now owns 824 shares of the biopharmaceutical company's stock valued at $32,000 after acquiring an additional 823 shares in the last quarter. Golden State Wealth Management LLC grew its holdings in shares of TG Therapeutics by 100.0% during the 1st quarter. Golden State Wealth Management LLC now owns 866 shares of the biopharmaceutical company's stock valued at $34,000 after acquiring an additional 433 shares in the last quarter. Finally, SVB Wealth LLC purchased a new position in TG Therapeutics in the first quarter valued at about $37,000. Hedge funds and other institutional investors own 58.58% of the company's stock.

Insider Buying and Selling at TG Therapeutics

In other news, Director Sagar Lonial sold 20,852 shares of TG Therapeutics stock in a transaction that occurred on Thursday, September 11th. The shares were sold at an average price of $32.24, for a total value of $672,268.48. Following the transaction, the director directly owned 94,061 shares of the company's stock, valued at $3,032,526.64. This trade represents a 18.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 10.64% of the stock is currently owned by company insiders.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.